Pricing Log in Create free account

enGene Therapeutics Inc (ENGN) vs Humacyte, Inc. (HUMA)

enGene Therapeutics Inc and Humacyte, Inc. are both Biotechnology companies. enGene Therapeutics Inc and Humacyte, Inc. are of similar size ($112.6M and $109.9M). enGene Therapeutics Inc has the higher net margin (0.00% vs −4,448.9%) and the higher return on invested capital (0.00% vs −433.7%). Across the 13 metrics below, enGene Therapeutics Inc leads on 10 and Humacyte, Inc. on 3.

Valuation

Metric ENGN HUMA Biotechnology median
P/E n/m n/m 10.60
P/S n/m 48.58 9.40
P/B 0.53 3.30 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.86 n/m 0.66
EV/Sales n/m 41.40 9.02
Earnings yield (117.61%) (111.36%) (32.88%)
Free cash flow yield (84.73%) (94.68%) (23.13%)

Profitability

Metric ENGN HUMA Biotechnology median
Gross margin — (494.58%) 68.51%
Operating margin 0.00% (5,240.78%) 0.00%
Net margin 0.00% (4,448.89%) 0.00%
Free cash flow margin 0.00% (4,599.72%) 0.00%
Return on equity (60.50%) (534.42%) (51.96%)
Return on assets (48.84%) (68.16%) (46.06%)
Return on invested capital 0.00% (433.66%) 0.00%

Growth

Metric ENGN HUMA Biotechnology median
Revenue growth (TTM) — 149.82% 6.76%
EPS growth (last fiscal year) (56.85%) 79.37% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ENGN HUMA Biotechnology median
Debt to equity 0.11 2.07 0.00
Current ratio 10.21 6.21 4.97
Net debt to EBITDA 1.42 (0.12) 1.01

Dividend

Metric ENGN HUMA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ENGN HUMA Biotechnology median
Market cap 112.59m 109.87m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack